Benzinga - Tue, 04 May 2021 08:08:07 -0400
Benzinga - Tue, 04 May 2021 07:01:25 -0400
Benzinga - Wed, 14 Apr 2021 09:05:29 -0400
Benzinga - Mon, 12 Apr 2021 07:02:10 -0400
Benzinga - Wed, 03 Mar 2021 09:30:51 -0400
Benzinga - Fri, 12 Feb 2021 10:53:16 -0400
Benzinga - Fri, 12 Feb 2021 09:31:55 -0400
load more
Sector: Health Care.Industry: Biotechnology
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian, and other solid tumors. The company is also advancing its proprietary late stage photodynamic therapy (PDT) platform that holds promise as a localized cutaneous or visceral tumor treatment as well as in other potential indications.

Earnings

see more
Q2 2021Est.ActualSurprise
EPS-0.220
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Related Companies

TickerCompanyChg %Mkt Cap
KTRAKintara Therapeutics5.56%40.7M

Kintara Therapeutics Company Questions & Answers

Q

How do I buy Kintara Therapeutics (KTRA) stock?

A

You can purchase shares of Kintara Therapeutics (NASDAQ: KTRA) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Kintara Therapeutics's (KTRA) main competitors?

A

Other companies in Kintara Therapeutics’s space includes: Immuron (NASDAQ:IMRN), Midatech Pharma (NASDAQ:MTP) and Geovax Labs (NASDAQ:GOVX).

Q

What is the target price for Kintara Therapeutics?

A

The latest price target for Kintara Therapeutics (NASDAQ: KTRA) was reported by Aegis Capital on 2021-02-03. The analyst firm set a price target for 7.00 expecting KTRA to rise to within 12 months (a possible 426.32% upside). 2 analyst firms have reported ratings in the last year.

Q

How much is Kintara Therapeutics (KTRA) stock ?

A

The stock price for Kintara Therapeutics (NASDAQ: KTRA) is $1.33 last updated Fri May 07 2021 20:00:02 GMT+0000 (Coordinated Universal Time).

Q

When is the next Kintara Therapeutics (KTRA) dividend?

A

There are no upcoming dividends for Kintara Therapeutics.

Q

When is Kintara Therapeutics (NASDAQ:KTRA) reporting earnings?

A
Kintara Therapeutics’s Q2 earnings are confirmed after-market from now on February 12, 2021.
Q

When is the upcoming split for KTRA?

A

There is no upcoming split for Kintara Therapeutics.